May 25, 2017

Protagonist Therapeutics Initiates Phase 1 Study with Novel Hepcidin Mimetic, PTG-300 read more

May 24, 2017

Protagonist Therapeutics Receives $1.34 Million SBIR Funding for Development of Biomarkers of IL-23 Receptor Antagonist Activity read more

May 10, 2017

Protagonist Therapeutics Reports First Quarter 2017 Financial Results read more